| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Anti-thrombin III Activity
MessageBUMCT: Performs for BUMCT and BUMCS
BDMC: Performs for BDMC and BUMCP
All other AZ locations send to SQL via STAT courier.
BCCH, WYMC and WMC send to SQL
BDMC: Performs for BDMC and BUMCP
All other AZ locations send to SQL via STAT courier.
BCCH, WYMC and WMC send to SQL
Test Code
ATIII
Alias/See Also
Performed at SQL, test code 3002
CPT Codes
85300
Preferred Specimen
3.2% sodium citrate - blue top tube
Instructions
The light blue capped tubes, containing 3.2% buffered sodium citrate, used for coagulation testing must be allowed to fill completely (after filling a small air space will normally be present).
See link below for specimen details, methodology, setup schedule and reference ranges.
Note: All sites (except BUMCT and BDMC, stats only) must separate and freeze plasma before sending to SQL-Papago.
Centrifuge within 4 hours of collection following the double spin process to produce platelet poor plasma.
REQUIRED - Aliquot platelet poor plasma into 2 separate transport vials: 1.0 mL into one vial and 0.5 mL into a second vial.
Immediately freeze vials in upright position for transportation to SQL.
If other coagulation tests are ordered, freeze a minimum of three plastic vials. Place in a specimen bag with a frozen label applied. See link below for specimen details, methodology, setup schedule and reference ranges for testing performed at SQL.
See link below for specimen details, methodology, setup schedule and reference ranges.
Note: All sites (except BUMCT and BDMC, stats only) must separate and freeze plasma before sending to SQL-Papago.
Centrifuge within 4 hours of collection following the double spin process to produce platelet poor plasma.
REQUIRED - Aliquot platelet poor plasma into 2 separate transport vials: 1.0 mL into one vial and 0.5 mL into a second vial.
Immediately freeze vials in upright position for transportation to SQL.
If other coagulation tests are ordered, freeze a minimum of three plastic vials. Place in a specimen bag with a frozen label applied. See link below for specimen details, methodology, setup schedule and reference ranges for testing performed at SQL.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Clotted
Serum received instead of Sodium Citrate plasma
Specimen past stability
Frozen plasma received thawed
Underfilled or Overfilled, blood/anticoagulant ratio must be 9/1; Specimens must be between 90% -110% full
Collected in a 3.8% Sodium Citrate tube instead of 3.2% Sodium Citrate tube
Drawn in outdated/expired tube
Hemolyzed, icteric, or lipemic sample
Serum received instead of Sodium Citrate plasma
Specimen past stability
Frozen plasma received thawed
Underfilled or Overfilled, blood/anticoagulant ratio must be 9/1; Specimens must be between 90% -110% full
Collected in a 3.8% Sodium Citrate tube instead of 3.2% Sodium Citrate tube
Drawn in outdated/expired tube
Hemolyzed, icteric, or lipemic sample
Clinical Significance
Antithrombin (AT), or Heparin Cofactor I, is the major inhibitor of blood coagulation and is essential for effective heparin therapy. By inhibiting the coagulation proteases, especially thrombin, FXa and FIXa, AT prevents uncontrolled coagulation and thrombosis. Antithrombin deficiency is associated with a high risk of thromboembolic disorders.
The Antithrombin assay can be used to exclude or diagnose hereditary deficiency in patients with a tendency toward thromboembolism, in pre-operative stages, before prescription of oral contraceptives, DIC, nephritic syndromes, liver diseases and in therapy with heparin or antithrombin concentrates.
In addition to congenital AT III deficiency, decreased AT III activity can be seen in association with severe liver disease, nephrotic syndrome, disseminated intravascular coagulation and other disease states where consumption is increased. AT III activity may also be decreased in patients on heparin therapy.
The Antithrombin assay can be used to exclude or diagnose hereditary deficiency in patients with a tendency toward thromboembolism, in pre-operative stages, before prescription of oral contraceptives, DIC, nephritic syndromes, liver diseases and in therapy with heparin or antithrombin concentrates.
In addition to congenital AT III deficiency, decreased AT III activity can be seen in association with severe liver disease, nephrotic syndrome, disseminated intravascular coagulation and other disease states where consumption is increased. AT III activity may also be decreased in patients on heparin therapy.
Additional Information
Anti-Thrombin III Activity
